These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11326673)

  • 1. The correlation of c-erbB-2 oncoprotein and established prognostic factors in human breast cancer.
    Sütterlin MW; Haller A; Gassel AM; Peters K; Caffier H; Dietl J
    Anticancer Res; 2000; 20(6D):5083-8. PubMed ID: 11326673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical detection of c-erbB-2 oncoprotein in patients with breast cancer.
    Chariyalertsak S; Chariyalertsak S; Cheirsilpa A; Sugano K; Ohkura H
    J Med Assoc Thai; 1996 Nov; 79(11):715-21. PubMed ID: 8997010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
    Aryandono T; Harijadi ; Ghozali A
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors.
    Erdogan S; Ergin M; Tuncer I
    Neoplasma; 2003; 50(5):326-30. PubMed ID: 14628084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D.
    Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C
    Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen value as a marker in breast cancer.
    Narita D; Cimpean AM; Anghel A; Raica M
    Neoplasma; 2006; 53(2):161-7. PubMed ID: 16575473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation between hemostatic parameters and prognostic/predictive factors in breast cancer.
    Yigit E; Gönüllü G; Yücel I; Turgut M; Erdem D; Cakar B
    Eur J Intern Med; 2008 Dec; 19(8):602-7. PubMed ID: 19046726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies.
    Vameşu S
    Rom J Morphol Embryol; 2007; 48(2):121-9. PubMed ID: 17641798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined overexpression of c-erbB-2 protein and epidermal growth factor receptor (EGF-R) could be predictive of early and long-term outcome in human breast cancer: a pilot study.
    Delarue JC; Terrier P; Terrier-Lacombe MJ; Mouriesse H; Gotteland M; May-Levin F
    Bull Cancer; 1994 Dec; 81(12):1067-77. PubMed ID: 7742595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
    Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
    Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study.
    Ko SS; Na YS; Yoon CS; Park JY; Kim HS; Hur MH; Lee HK; Chun YK; Kang SS; Park BW; Lee JH
    Int J Surg Pathol; 2007 Apr; 15(2):98-109. PubMed ID: 17478762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome.
    Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A
    Int J Oncol; 2002 Nov; 21(5):981-7. PubMed ID: 12370744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-erbB2 oncoprotein: prognostic marker in breast cancer.
    Roşian A; Lazăr E; Dema A
    Rom J Morphol Embryol; 2005; 46(2):99-104. PubMed ID: 16286993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
    Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunohistochemical study on the expression of c-erbB2 oncoprotein in breast tumors].
    Zhang Z; Xu G; Liu S
    Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):287-9. PubMed ID: 11038761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.